MicroRNA-10b and the clinical outcomes of various cancers: A systematic review and meta-analysis

The impact of miR-10b expression on the survival outcome of patients with cancers is still controversial.

A systematic review and meta-analysis was performed to determine its implication on the survival of cancer patients. We carried out an electrical literature search to identify the eligible studies published in PubMed, Web of Science and Embase together with the Chinese databases.

In total, 28 studies of 23 articles enrolling 3134 patients were included for this meta-analysis, of which 25 studies reported overall survival (OS), 4 studies evaluated recurrence-free survival (RFS) and 3 studies were related to disease-free survival (DFS). As a result, this meta-analysis revealed that up-regulation of miR-10b could confer an unfavorable factor for OS (HR=1.853, 95% CIs: 1.521-2.258, P<0.01) but not DFS (HR=1.309, 95% CIs: 0.699-2.453, P=0.4) or RFS (HR=2.692, 95% CIs: 0.877-8.265, P=0.084). Additionally, further analysis also suggested that overexpression of miR-10b predicted the shorter OS for the patient with different types of cancers, which contained lung cancer, breast cancer, glioma, colorectal cancer and gastric carcinoma. Subgroup analyses were also conducted according the region, sample size, system and miR-10b detection assay and statistical method.

This study shows that augmented expression of miR-10b strongly predicts poor prognosis for patients with cancers.